Premier labs face soft demand and shifting tenant mixes
- ARE is the leading landlord for life science lab space in top research hubs like Boston, San Francisco, and San Diego.
- The core business is under pressure with operating occupancy falling to 86.9% in the second quarter of 2026.
- Same-property net operating income dropped 10.6% year over year in the second quarter.
- A major threat was removed when the government stopped a planned 15% cap on NIH funding.
- Leasing has shifted sharply away from public biotech toward advanced technology and life science tools to fill vacant space.
Great assets in a tough cycle
Alexandria owns some of the best lab real estate in North America. Its campuses sit near universities, hospitals, and talent pools that biotech and pharma companies need. That is the heart of the bull case. The company still has long leases, high rent collection, and a tenant base where investment-grade or publicly traded large-cap tenants make up 57% of annual rental revenue.
The problem is that the life science real estate market has turned hard. Operating occupancy fell to 86.9% as of June 30, 2026. Same-property net operating income fell 10.6% compared to the prior year. Rental rate changes on renewed spaces turned negative, showing that landlords have lost pricing power.
To combat weak biotech demand, Alexandria is shifting its focus. In the second quarter of 2026, public biotech accounted for only 6% of leasing volume. Instead, the company leased space to advanced technology and life science device companies. This pivot secures needed cash flow, but management admits it often comes with lower overall investment returns.
Finn views the situation with caution. The company took a $222.5 million impairment charge in the second quarter on non-core assets in oversupplied markets like Toronto and peripheral San Diego. ARE can recover if biotech funding improves, but until then, the story is about managing debt through asset sales and filling empty space with alternative tenants.
Renting labs to science tenants
ARE is a real estate investment trust, or REIT. A REIT owns income-producing property and pays out much of its taxable income to shareholders. Alexandria makes its money by building Class A and Class A+ lab and office space for life science tenants.
The company relies on long-term leases. Most of its leases are triple net, meaning tenants pay property costs like taxes, insurance, utilities, repairs, and common area maintenance on top of rent. This structure helps protect the company from inflation and rising property expenses.
Its edge comes from location and scale. ARE builds large megacampus clusters where tenants can start small, expand, and stay in the same network. As of June 30, 2026, 80% of its total annual rental revenue came from these megacampuses.
The model struggles when tenants stop growing. That is happening now. Biotech funding remains selective, and more lab supply in top markets gives tenants more choices. This pushes landlords to cut rents, offer free rent, or pivot spaces to lower-cost tech uses to maintain occupancy.
What Alexandria owns
Megacampus lab properties
These are large clusters of lab and office buildings in top science hubs. They produced 80% of total annual rental revenue as of June 30, 2026.
Operating lab and office portfolio
The operating base is where current rent comes from, but occupancy has fallen to 86.9% as of the second quarter of 2026.
Development and redevelopment pipeline
ARE has active construction projects, but weak demand is forcing the company to pivot some lab spaces to lower-cost advanced tech uses.
Triple-net lease platform
Most leases pass operating costs directly to tenants, helping protect property margins from inflation.
Assets for sale
Management is executing a $2.9 billion disposition program to recycle capital and reduce debt.
Revenue is mostly megacampus rent
ARE reports one real estate business, so this page uses the latest disclosed portfolio mix by total annual rental revenue as of June 30, 2026.
What could go wrong
Occupancy keeps falling
High impact · High oddsOperating occupancy fell to 86.9% as of June 30, 2026. Lower occupancy means less rent and weaker property profit. The company continues to face a fundamental oversupply in key markets like Boston, San Francisco, and San Diego.
Rents reset lower
High impact · High oddsRental rate changes on renewed spaces turned negative in the second quarter of 2026, dropping 4.3% on a cash basis. That signals tenants have more bargaining power, forcing landlords to cut prices to keep buildings full.
Asset values decline further
High impact · Medium oddsThe company recorded $222.5 million in real estate impairments during the second quarter of 2026 due to oversupply in peripheral markets. If more asset values fall, ARE may get less cash than planned from its $2.9 billion disposition program.
Biotech funding stays tight
High impact · High oddsA cautious venture capital funding environment slows company formation and lab demand. Public biotech accounted for only 6% of leasing volume in the recent quarter, forcing ARE to rely on other tenant types.
Development spaces fail to lease
Medium impact · Medium oddsThe company has 1.4 million square feet of active construction projects slated for delivery in 2027 and 2028. If leasing remains slow, new space will drain cash, and pivoting to tech uses might yield lower returns.
In one breath
Why did ARE stock fall after a big EPS beat earlier this year?
The EPS beat in Q1 2026 came mainly from a one-time accounting gain on buying back debt below face value. Investors focused more on the revenue miss and weak tenant demand.
Is Alexandria Real Estate a normal office REIT?
No. ARE focuses on specialized lab and life science campuses, not standard office buildings. That niche has unique tenant needs but is tied closely to biotech funding.
What needs to improve for the bull case to work?
Occupancy needs to stabilize, rental rates on renewals need to stop falling, and the $2.9 billion asset sale program needs to close at reasonable prices.
